文献速递临床试验与 GCP基础与转化研究

Ceperognastat治疗早期症状性阿尔茨海默病的随机临床试验

Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项2期双盲随机安慰剂对照试验在5国72个中心纳入327例早期症状性AD患者,评估口服OGA抑制剂ceperognastat的疗效与安全性。主要终点分析人群为259例基线tau水平低至中度者,100周时iADRS评分未见临床获益,3 mg组疾病进展比安慰剂更差,且严重不良事件更多。

要点

  • ceperognastat未减缓早期症状性AD的疾病进展
  • 3 mg组疾病进展较安慰剂增加32%,严重不良事件比例更高
  • 仅3 mg组侧颞叶tau PET摄取增幅小于安慰剂,但无临床意义

核心结论

  • ceperognastat未能减缓早期症状性AD的疾病进展。

研究设计与样本

  • 双盲、随机、安慰剂对照2期研究,2021年9月至2024年8月在5国72个中心开展,并有至2025年5月的治疗后观察延长期。
  • 327例受试者按1:1:1随机接受每日一次口服ceperognastat 0.75 mg(n=110)、3 mg(n=108)或安慰剂(n=108);主要终点人群为259例基线tau低至中度者。

主要发现

  • 100周时iADRS自基线后验均值变化:0.75 mg组-8.39、3 mg组-13.27、安慰剂组-10.07。
  • 相对安慰剂的疾病进展比:0.75 mg组0.84(95%CrI 0.66-1.04,即减缓16%),3 mg组1.32(95%CrI 1.10-1.58,即增快32%)。
  • 次要临床终点均未显示获益;基线至76周仅3 mg组侧颞叶tau PET标准化摄取值比增幅显著小于安慰剂(P=.04)。
  • 磁共振体积测定显示ceperognastat组全脑体积丢失少于安慰剂(0.75 mg组少43.2%、3 mg组少49.5%,均P<.001)。
  • 治疗中出现严重不良事件:0.75 mg组13例(12.0%)、3 mg组29例(26.4%)、安慰剂组17例(15.7%)。

关键数值与推荐

  • 主要终点成功标准为贝叶斯概率疾病进展模型下,较安慰剂减缓≥25%的概率≥60%。
  • 主要终点为iADRS评分变化;6项次要终点包括ADAS-Cog13、ADCS-ADL、CDR-SB、MMSE、tau PET和体积磁共振成像。

临床怎么用

  • 该结果不支持将ceperognastat用于早期症状性AD的疾病修饰治疗。
  • 3 mg组严重及重度治疗中出现不良事件更多,提示该剂量安全性需关注。

局限性

  • 主要终点分析仅纳入基线tau低至中度者,排除了高tau水平个体,外推受限。
  • 为2期研究,样本量有限,随访至100周,长期疗效与安全性未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Inhibiting O-linked N-acetylglucosaminidase (OGA) is hypothesized to slow accumulation of aggregated, hyperphosphorylated tau and neurofibrillary tangle formation. OBJECTIVE: To evaluate the efficacy and safety of the potent oral OGA inhibitor ceperognastat in early symptomatic Alzheimer disease (AD). DESIGN, SETTING, AND PARTICIPANTS: This double-blind, randomized, placebo-controlled phase 2 study was conducted at 72 sites in 5 countries from September 2021 to August 2024, with a posttreatment observational extension period through May 2025. The primary outcome population comprised participants with early symptomatic AD and biomarker evidence of tau pathology, including low to medium baseline tau levels (excluding individuals with high levels), as measured by positron emission tomography (PET) with flortaucipir F18. INTERVENTION: Participants were randomized 1:1:1 to receive once-daily, oral ceperognastat at doses of 0.75 mg (n = 110) or 3 mg (n = 108) or placebo (n = 108). MAIN OUTCOMES AND MEASURES: The primary outcome was change in Integrated AD Rating Scale (iADRS) score. The success criterion was a 60% or greater probability of achieving greater than or equal to 25% slower progression vs placebo using a bayesian probabilistic disease progression model. The 6 secondary outcomes were Alzheimer's Disease Assessment Scale-Cognitive Subscale, 13-item version; Alzheimer's Disease Cooperative Study-Activities of Daily Living scale; Clinical Dementia Rating-Sum of Boxes; Mini-Mental State Examination; tau PET; and volumetric magnetic resonance imaging. RESULTS: Of the 327 randomized participants (mean age, 73.4 years; 201 [61.5%] females), 259 (87 receiving ceperognastat 0.75 mg, 86 receiving ceperognastat 3 mg, and 86 receiving placebo) with low to medium baseline tau levels were included in the primary outcome population (mean age, 74.3 years; 161 [62.2%] females). In this population, no clinically meaningful benefit vs placebo was observed for the primary end point (iADRS score) at 100 weeks: posterior mean change from baseline was -8.39 with ceperognastat 0.75 mg, -13.27 with ceperognastat 3 mg, and -10.07 with placebo. The disease progression ratio relative to placebo was 0.84 (95% credible interval [CrI], 0.66-1.04) for the ceperognastat 0.75 mg group and 1.32 (CrI, 1.10-1.58) for the ceperognastat 3 mg group, corresponding to 16% less and 32% greater progression, respectively. No benefits were demonstrated for secondary clinical end points. From baseline to 76 weeks, least-squares mean change in standardized uptake value ratio on PET showed a statistically significantly smaller increase (P = .04) vs placebo only for the ceperognastat 3 mg group in the lateral temporal lobe. Volumetric magnetic resonance imaging showed less whole brain volume loss in participants treated with ceperognastat vs placebo (43.2% [ceperognastat 0.75 mg] and 49.5% [ceperognastat 3 mg] less vs placebo; both P < .001). The ceperognastat 3 mg group had more serious (ceperognastat 0.75 mg: n = 13 [12.0%]; ceperognastat 3 mg: n = 29 [26.4%]; placebo: n = 17 [15.7%]) and severe (ceperognastat 0.75 mg: n = 7 [6.5%]; ceperognastat 3 mg: n = 15 [13.6%]; placebo: n = 7 [6.5%]) treatment-emergent adverse events. CONCLUSIONS AND RELEVANCE: Ceperognastat did not slow disease progression of early symptomatic AD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05063539.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Fleisher AS, Munsie L, Mancini M, et al. Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial. JAMA. 2026. PMID: 42441396. doi:10.1001/jama.2026.12768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。